Advanced search
Publication Cover
Leukemia & Lymphoma Volume 49, 2008 - Issue 11
Submit an article Journal homepage
207
Views
22
CrossRef citations to date
0
Altmetric
Letters to the Editor

OCT1 (SLC22A1) R61C polymorphism and response to imatinib treatment in chronic myeloid leukemia patients

Otto Zach First Department of Internal Medicine, Elisabethinen Hospital, Linz, AustriaCorrespondence[email protected]
,
Otto Krieger First Department of Internal Medicine, Elisabethinen Hospital, Linz, Austria
,
Mathilde Foedermayr First Department of Internal Medicine, Elisabethinen Hospital, Linz, Austria
,
Barbara Zellhofer First Department of Internal Medicine, Elisabethinen Hospital, Linz, Austria
&
Dieter Lutz First Department of Internal Medicine, Elisabethinen Hospital, Linz, Austria
Pages 2222-2223 | Received 06 May 2008, Accepted 03 Jul 2008, Published online: 01 Jul 2009

Citations (22)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (1)

Jingguo Li, Zhengyi Yang & Biguang Tuo. (2019) Role of OCT1 in hepatocellular carcinoma. OncoTargets and Therapy 12, pages 6013-6022.
Read now

Articles from other publishers (21)

Mohammad Shameem, Alireza Jian Bagherpoor, Ali Nakhi, Peter Dosa, Gunda Georg & Fekadu Kassie. (2023) Mitochondria‐targeted metformin (mitomet) inhibits lung cancer in cellular models and in mice by enhancing the generation of reactive oxygen species. Molecular Carcinogenesis.
Crossref
Fangrui Xiu, Magdalena Rausch, Zhibo Gai, Shanshan Su, Shijun Wang & Michele Visentin. (2023) The Role of Organic Cation Transporters in the Pharmacokinetics, Pharmacodynamics and Drug–Drug Interactions of Tyrosine Kinase Inhibitors. International Journal of Molecular Sciences 24:3, pages 2101.
Crossref
Robert Gharavi & Hazem E. Hassan. 2018. Genomics-Driven Healthcare. Genomics-Driven Healthcare 133 175 .
Claudia Neul, Elke Schaeffeler, Alex Sparreboom, Stefan Laufer, Matthias Schwab & Anne T. Nies. (2016) Impact of Membrane Drug Transporters on Resistance to Small-Molecule Tyrosine Kinase Inhibitors. Trends in Pharmacological Sciences 37:11, pages 904-932.
Crossref
Mohamed A. M. Ali. (2016) Chronic Myeloid Leukemia in the Era of Tyrosine Kinase Inhibitors: An Evolving Paradigm of Molecularly Targeted Therapy. Molecular Diagnosis & Therapy 20:4, pages 315-333.
Crossref
C Arimany-Nardi, H Koepsell & M Pastor-Anglada. (2015) Role of SLC22A1 polymorphic variants in drug disposition, therapeutic responses, and drug–drug interactions. The Pharmacogenomics Journal 15:6, pages 473-487.
Crossref
D B Watkins, T P Hughes & D L White. (2015) OCT1 and imatinib transport in CML: is it clinically relevant?. Leukemia 29:10, pages 1960-1969.
Crossref
Heidi J. Einolf & Imad Hanna. 2014. Predictive ADMET. Predictive ADMET 353 396 .
Jacob Grinfeld, Gareth Gerrard, Mary Alikian, Juan Alonso-Dominguez, Sakuntala Ale, Mikel Valgañon, Georgios Nteliopoulos, Deborah White, David Marin, Corinne Hedgley, Stephen O'Brien, Richard Clark, John M. Goldman, Dragana Milojkovic, Jane F. Apperley & Letizia Foroni. (2013) A common novel splice variant of SLC22A1 ( OCT1) is associated with impaired responses to imatinib in patients with chronic myeloid leukaemia . British Journal of Haematology 163:5, pages 631-639.
Crossref
Elisa Herraez, Elisa Lozano, Rocio I.R. Macias, Javier Vaquero, Luis Bujanda, Jesus M. Banales, Jose J.G. Marin & Oscar Briz. (2013) Expression of SLC22A1 variants may affect the response of hepatocellular carcinoma and cholangiocarcinoma to sorafenib . Hepatology 58:3, pages 1065-1073.
Crossref
Sophie L. Stocker, Arian Emami Riedmaier, Matthias Schwab & Kathleen M. Giacomini. 2013. Pharmacogenomics of Human Drug Transporters. Pharmacogenomics of Human Drug Transporters 171 208 .
Athina GiannoudisLihui WangAndrea L. JorgensenGeorge Xinarianos, Andrea DaviesSudeep Pushpakom, Triantafilos LiloglouJieying-Eunice Zhang, Gemma AustinTessa L. HolyoakeLetizia ForoniPanagiotis D. Kottaridis, Martin C. Müller, Munir Pirmohamed & Richard E. Clark. (2013) The hOCT1 SNPs M420del and M408V alter imatinib uptake and M420del modifies clinical outcome in imatinib-treated chronic myeloid leukemia. Blood 121:4, pages 628-637.
Crossref
Henriette E. Meyer zu Schwabedissen, Markus Grube & Heyo K. Kroemer. 2012. Pharmacogenetics and Individualized Therapy. Pharmacogenetics and Individualized Therapy 101 148 .
Jason A. Sprowl, Torben S. Mikkelsen, Hugh Giovinazzo & Alex Sparreboom. (2012) Contribution of tumoral and host solute carriers to clinical drug response. Drug Resistance Updates 15:1-2, pages 5-20.
Crossref
Bethzaida Astorga, Theresa M. Wunz, Mark Morales, Stephen H. Wright & Ryan M. Pelis. (2011) Differences in the substrate binding regions of renal organic anion transporters 1 (OAT1) and 3 (OAT3). American Journal of Physiology-Renal Physiology 301:2, pages F378-F386.
Crossref
Bruno Stieger & Peter J Meier. (2011) Pharmacogenetics of drug transporters in the enterohepatic circulation. Pharmacogenomics 12:5, pages 611-631.
Crossref
Xiao-Jun Huang, Lan-Ping Xu, Kai-Yan Liu, Dai-Hong Liu, Huan Chen, Yan-Rong Liu, Yu-Hong Chen, Wei Han & Yu Wang. (2011) Individualized Intervention Guided by BCR-ABL Transcript Levels after HLA-Identical Sibling Donor Transplantation Improves HSCT Outcomes for Patients with Chronic Myeloid Leukemia. Biology of Blood and Marrow Transplantation 17:5, pages 649-656.
Crossref
Yuji Yamakawa, Akinobu Hamada, Reiko Nakashima, Misato Yuki, Chie Hirayama, Tatsuya Kawaguchi & Hideyuki Saito. (2011) Association of Genetic Polymorphisms in the Influx Transporter SLCO1B3 and the Efflux Transporter ABCB1 With Imatinib Pharmacokinetics in Patients With Chronic Myeloid Leukemia. Therapeutic Drug Monitoring 33:2, pages 244-250.
Crossref
Karel Eechoute, Alex Sparreboom, Herman Burger, Ryan M. Franke, Gaia Schiavon, Jaap Verweij, Walter J. Loos, Erik A.C. Wiemer & Ron H.J. Mathijssen. (2011) Drug Transporters and Imatinib Treatment: Implications for Clinical Practice. Clinical Cancer Research 17:3, pages 406-415.
Crossref
Takeru Nambu, Akinobu Hamada, Reiko Nakashima, Misato Yuki, Tatsuya Kawaguchi, Hiroaki Mitsuya & Hideyuki Saito. (2011) Association of SLCO1B3 Polymorphism with Intracellular Accumulation of Imatinib in Leukocytes in Patients with Chronic Myeloid Leukemia. Biological & Pharmaceutical Bulletin 34:1, pages 114-119.
Crossref
Anne T. Nies, Hermann Koepsell, Katja Damme & Matthias Schwab. 2011. Drug Transporters. Drug Transporters 105 167 .

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.